Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0WOUMV
ADC Name	RG-7841
Synonyms	Anti-Ly6E; DLYE-5953A; DLYE5953A; RG 7841 Click to Show/Hide
Organization	Genentech, Inc.
Drug Status	Phase 1
Indication	In total 4 Indication(s) HER2(-) breast cancer [ICD11:2C60-2C65] Phase 1 Non-small cell lung cancer [ICD11:2C25] Phase 1 Ovarian cancer [ICD11:2C73] Phase 1 Pancreatic cancer [ICD11:2C10] Phase 1
Drug-to-Antibody Ratio	4
Structure
	3D MOL	2D MOL
Antibody Name	MLYE4489A		Antibody Info
Antigen Name	Lymphocyte antigen 6E (LY6E)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin
Puchem SID	472419468 , 404720137
ChEBI ID	CHEMBL4297935

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT02092792	Phase 1	A phase 1, open-label study evaluating the safety and tolerability of escalating doses of DLYE5953A in patients with refractory solid tumors.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	17.76%
Patients Enrolled	Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, histologically or cytologically documented advanced or metastatic breast, ovarian, pancreatic, NSCLC, head and neck squamous cell carcinoma, or gastric cancer in dose escalation, adequate hematologic and end organ function, and measurable disease per RECIST v1.1.
Administration Dosage	Intravenously at doses of 0.20, 0.40, 0.80, 1.60, or 2.40 mg/kg once every 3 weeks (Q3W).
*Related Clinical Trial*
NCT Number	NCT02092792	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label study evaluating the safety and tolerability of escalating doses of DLYE5953A in patients with refractory solid tumors.
Primary Endpoint	The confirmed overall objective response rate was 17.76%. All responders (8/68 patients) had PR,and all had received the RP2D dose of 2.40 mg/kg. This included three patients with MBC, and five patients in the NSCLC expansion cohort (5/25; 20%).
Other Endpoint	The recommended phase II dose (RP2D) was 2.40 mg/kg Q3W. No dose-limiting toxicities were identified during dose escalation (0.20-2.40 mg/kg; n = 20).

References

Ref 1	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. Clin Cancer Res. 2020 Nov 1;26(21):5588-5597.